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INTRODUCTION 
The non-rejection of the implanting blastocyst is one of the most fascinating topics 
in reproductive immunology. The interest in it has enormously increased in the last 
years since, with the development of the in vitro fertilization-embryo transfer (IVF-ET) 
technique, the great number of very early abortions (biochemical pregnancies) has 
become apparent; thus, the implantation rate must be considered as the real limit- 
ing factor in all the assisted reproductive techniques. It seems likely that several im- 
munological mechanisms such as the modification of the mother immune response 
by hormones and by non-hormonal substances, fetal and maternal suppressor cells, 
and maternal blocking antibodies are involved in the maintenance of pregnancy.'-5 
An immunological recognition of the blastocyst has been claimed to be a necessary 
prerequisite for a successful pregnancy. It has been further postulated that failure in 
this immunological recognition could lead to repeated unexplained abortions.6 So far 
immunization treatment of women with recurrent abortion has been introduced, using 
different protocols: third party  leukocyte^,^ husband's leukocytes,6 or trophoblast 
membrane preparation.8 Recently, a passive immunization treatment by using Ig from 
a donor pool (IVIG) has been proposed as well, which should provide immunological 
protection of pregnancy in the same way as the previous techniques.9 
Considering the very high reliability of this technique, which has no side effects, 
a pilot study was undertaken to examine the possibility to extend this treatment to 
two other groups: 1) women with two or more previous very early pregnancy failures 
(including biochemical pregnancies) following assisted reproductive techniques; 
2) women with repeated (n 2 3) unsuccessful embryo transfers either uterine or tubal. 
So far we have treated 19 women (12 group A and 7 group B) obtaining 5 ongoing 
pregnancies out of a total of nine positive P-HCG. 
MATERIALS AND METHODS 
Inclusion criteria for the passive immunization protocol were: 1) women with two 
or more previous very early pregnancy failures (including biochemical pregnancies) 
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TABLE 1. Results Obtained Using the Intravenous Immunoglobulin Protocol 
Patients Cause of Infertility Attempts Attempts Results 
Previous Current 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
Tubal 
Male Factor 
Unexplained 
Unexplained 
Tubal 
Unexplained 
Tubal + male factor 
Unexplained 
Unexplained 
Unexplained 
Tubal 
Unexplained 
Unexplained 
Unexplained 
Tubal + male factor 
Unexplained 
Unexplained 
Unexplained 
Tubal 
3 UETQ 2 BP 
4 IUI 
3 DIPI 
2 UET 
1 TET I BP 
4 IUI 
3 UET 
4 DIPI 
1 UET 
2 TET 
3 UET 1 EA 
5 IUI 
3 DIPI 
2 GIFT 1 BP 
1 UET 1 EA 
3 UET 
3 DIPI 
3 GIFT 1 BP 
1 UET 1 EA 
4 IUI 
3 DIPI 
2 UET 
1 TET 2 BP 
4 DIPI 
1 UET 
2 TET 
4UET 1 EA 
1 BP 
4 DIPI 
3 UET 
3 IUI 
2 DIPI 
1 GIFT 
1 UET 2 EA 
4 IUI 
3 DIPI 
2 UET 
1 TET 1 BP 
3 UET 1 BP 
3 IUI 
3 DIPI 
1 GIFT 1 EA 
1 UET 1 BP 
2 IUI 
4 DIPI 
1 GIFT 1 EA 
I UET I BP 
4 IUI 
3 DIPI 
2 UET 
1 TET 1 BP 
3 UET 1 BP 
IVF 
ZIFT 
ZIFT 
ZIFT 
IVF 
ZIFT 
IVF 
ZIFT 
ZIFT 
ZIFT 
IVF 
ZIFT 
ZIFT 
ZIFT 
IVF 
ZIFT 
ZIFT 
ZIFT 
IVF 
No pregnancy 
No pregnancy 
Ongoing pregnancy (14 week) 
No pregnancy 
Ongoing pregnancy (16 week) 
Ongoing pregnancy (8 week) 
No pregnancy 
Early abortion (7 week) 
No pregnancy 
Ongoing pregnancy (20 week) 
No pregnancy 
No pregnancy 
No pregnancy 
Ongoing pregnancy (15 week) 
No pregnancy 
Biochemical pregnancy 
Biochemical pregnancy 
No pregnancy 
Earlv abortion (7 week) 
a Abbreviations: IUI = Intrauterine Insemination; DIPI = Direct IntraPeritoneal Insemination; 
UET = Uterine Embryo Transfer; TET = Tubal Embryo Transfer; EA = Early Abortion; BP = 
Biochemical Pregnancy. 
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following assisted reproductive techniques; 2) women with repeated (n > 3) unsuc- 
cessful embryo transfers either uterine or tubal. Informed consent was obtained from 
19 women: 12 in group A and 7 in group B. The Intra-Venous Immunoglobulin (IVIG) 
protocol we have adopted has been: 20g of human Ig from a pool of 100 donors (Endo- 
bulin, Immuno) in slow infusion at the beginning of ovarian hyperstimulation by ex- 
ogenous gonadotropins for IVF, followed by a second dose of 15g at the moment of 
positive 0-HCG and then every 3 weeks up to week 20. The blocking capacity of 
sera was investigated in one way mixed lymphocytes culture (MLC): lymphocytes 
were separated by Ficoll gradient centrifugation and then transferred in RPMI sup- 
plemented with 10% serum; all sera from patients were heat inactivated; the inhibition 
exerted by each single serum was determined as a percentage of the response in AB 
serum (100 X cpm in own serumkpm in AB serum). 
RESULTS AND DISCUSSION 
By using the IVIG technique, as reported in TABLE 1, we have obtained 9 preg- 
nancies out of a total of 19 treated women. Five of these have an ongoing pregnancy 
(between 8 and 20 weeks), 2 have had a biochemically detectable pregnancy and 2 
a very early abortion (within 8 weeks). Four out of the 5 pregnant women had an 
abnormal one way MLC suggesting a deficient blocking activity in the serum. These 
very preliminary results seem to show a positive effect of IVIG treatment in these 
indications of 55.5% (5 out of 9) in a population with a well documented inability 
to obtain a successful implantation. Considering the MLC results (TABLE 2) we can 
observe a significantly higher success rate of WIG treatment in those patients with 
a presumptive lower serum blocking activity. Furthermore, the IVIG technique has 
some important advantages over the other immunization techniques, such as simplicity 
of use and the absence of major side effects,I0 particularly long-term ones, both on 
the mother and on the fetus. 
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